China's HMO Breakthrough: Domestic Supply Chain Matures as Hongmo Bio Earns Three Key Approvals

For years, food manufacturers seeking HMO (human milk oligosaccharide) ingredients faced a familiar constraint: the supply chain ran through Europe and North America. Chinese companies depended on imported ingredients from major Western players—a situation that created vulnerability in pricing, delivery timelines, and regulatory navigation.

That dependency is ending. A domestic champion has emerged, and China's HMO supply chain has reached a new level of maturity that changes the equation for food manufacturers globally.

The Old Problem: A Supply Chain Bottleneck

HMO ingredients—particularly 2'-fucosyllactose (2'-FL) and lacto-N-neotetraose (LNnT)—were long controlled by a handful of international companies. For Chinese food manufacturers, this meant:

• Limited negotiating power on pricing and volume commitments
• Extended lead times tied to international logistics
• Regulatory complexity when navigating both Chinese and international approval processes
• Supply risk exposed to trade disruptions, shipping delays, and currency fluctuations

The result was a barrier to entry that discouraged smaller manufacturers and created dependency for larger ones. The HMO opportunity was real, but the supply chain to capitalize on it was constrained.

The Domestic Champion: Humacro (虹摹生物) Takes the Lead

The turning point came through Humacro (虹摹生物), a subsidiary of Mengniu Dairy (蒙牛乳业), which has systematically built China's domestic HMO manufacturing capability from the ground up.

The timeline tells the story of accelerating momentum:

October 2023: Humacro became the first Chinese company to receive National Health Commission approval for 2'-FL production—the initial breakthrough that established domestic HMO manufacturing capability.

May 2025: Humacro secured approval for LNnT, becoming China's first company to hold approvals for both 2'-FL and LNnT. This dual approval enabled more complex HMO formulations and reduced dependence on multiple international suppliers.

February 2026: Humacro achieved a milestone no other Chinese company has matched: approval for 3'-sialyllactose (3'-SL). With all three major HMOs approved, Humacro became China's only company with simultaneous approval for 2'-FL, LNnT, and 3'-SL.

This three-approval achievement is transformative. It means Chinese food manufacturers can now source all three primary HMOs from a single domestic supplier—streamlining procurement, reducing logistics complexity, and enabling more sophisticated product formulations.

Quality That Competes: Chinese HMO Reaches International Standards

The domestic breakthrough isn't just about availability—it's about quality. Humacro's 2'-FL consistently achieves purity levels exceeding 99%, surpassing the international average and meeting the stringent requirements for premium infant nutrition products.

Beyond purity, Humacro achieved regulatory recognition on the global stage. Their 2'-FL became the first Chinese HMO ingredient to receive GRAS (Generally Recognized As Safe) certification from the U.S. Food and Drug Administration—a significant endorsement that opens doors to international markets and validates quality standards against the world's most demanding regulatory framework.

The company simultaneously secured approval from China's National Health Commission, creating a rare dual-regulatory validation that positions Chinese HMO ingredients for both domestic and export applications.

Global Recognition: World Dairy Innovation Award

In 2025, Humacro received the World Dairy Innovation Award for "Best Startup Brand"—the only Chinese HMO ingredient company to earn this recognition. The award, decided by an international panel of industry experts, signals that Chinese HMO manufacturing has reached a level of quality and innovation that competes with established Western suppliers.

This global validation matters for food manufacturers evaluating HMO sourcing strategies. When a Chinese supplier earns recognition from international industry bodies, it reduces the perceived risk of domestic sourcing and establishes credibility for export-oriented product development.

What This Means for Food Manufacturers

The maturation of China's domestic HMO supply chain creates tangible advantages for food and infant nutrition manufacturers:

Supply Security: Domestic production eliminates exposure to international shipping disruptions, port congestion, and geopolitical trade risks. Manufacturers can plan production schedules with greater confidence in ingredient availability.

Cost Competitiveness: Reduced logistics costs and elimination of import tariffs create pricing advantages. Domestic suppliers can offer competitive terms without the overhead of international distribution networks.

Regulatory Alignment: Chinese-approved HMO ingredients come with regulatory documentation aligned to National Health Commission requirements. This streamlines the product approval process and reduces compliance uncertainty.

Supply Chain Resilience: Sourcing from domestic suppliers enables shorter response times for volume adjustments, rush orders, and quality issue resolution. The distance between manufacturer and supplier shrinks from transoceanic to domestic.

Customization Flexibility: Domestic suppliers can collaborate more closely on formulation development, specification adjustments, and technical support. This partnership approach is difficult to achieve with large international ingredient conglomerates.

The Strategic Signal: Domestic HMO Is Now, Not Later

For manufacturers who have been waiting for the domestic HMO supply chain to "catch up," that moment has arrived. The question is no longer whether Chinese HMO ingredients are viable—they have proven themselves through regulatory approval, quality certification, and international recognition.

What was once a strategic consideration is now a competitive imperative. Manufacturers who secure reliable HMO supply chains now will be positioned to capitalize on the rapidly growing functional food market. Those who delay risk falling behind competitors who have already established HMO-enabled product lines and supplier relationships.

The regulatory pathway is clear, the supply chain is mature, and the market opportunity is expanding. The window for establishing HMO supply partnerships is open—proactive engagement today creates advantages that compound over time.

Morika Bio (www.morikabio.com) provides comprehensive HMO ingredient solutions for food and supplement manufacturers, connecting buyers with reliable domestic HMO supply that meets international quality standards. Our team supports sourcing, regulatory compliance, and formulation guidance for manufacturers developing HMO-enabled products. Contact us to explore supply partnerships.

References

1. Humacro Three HMO Approvals: https://app.xinhuanet.com/news/article.html?articleId=743e7a3d84cec8e02698724926ce36ca
2. Abbott HMO Clinical Research: https://www.abbott.com/en-us/corpnewsroom/nutrition-health-and-wellness/with-infant-formula-innovating-means-getting-ever-closer-to-breast-milk
3. Global HMO Market Forecast: https://www.yhresearch.co.jp/reports/1257082/hmo-infant-formula
4. Wyeth 10-HMO Global Launch: http://www.sznews.com/news/content/2025-08/04/content_31652238.htm
5. CIIE HMO Product Wave: http://m.163.com/dy/article/KE307P3905383MLM.html